Phase 1Completed

Assessment of Effect of Rapastinel on Driving Performance

A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants

Sponsor
Naurex, Inc, an affiliate of Allergan plc (Industry)
Enrollment
107 enrolled
Conditions
Driving Performance
Interventions
Rapastinel; Alprazolam; Ketamine; Rapastinel Matched Placebo; Alprazolam Matched Placebo; Ketamine Matched Placebo
Ages
adults, older adults
Registry
NCT03814733

Full record on ClinicalTrials.gov

From the registry

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.

Primary outcomes

  • Simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with placebo and positive control (alprazolam)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started